Contact: Ralph Kauten
(608) 441-2950
RalphK@Quintbio.com
Madison, WI., Sept. 16 — Quintessence Biosciences, Inc. announced today that it will present at BioContact Quebec 2004, a biopharmaceutical partnership symposium at 4:00 p.m. eastern time on October 7, 2004.
The conference is being held at the Chateau Frontenac, Quebec Canada and represents a gathering of over 1,200 participants from the pharmaceutical and biotechnology industries. Quintessence’s presentation will provide the first public look at the Company’s scientific progress toward development of a cancer therapy that works by a novel mechanism of action.
The cancer therapies under development at Quintessence Biosciences are based upon the Company’s proprietary EVade™ Ribonuclease technology. This technology allows the Company to modify human proteins, thereby converting normally inert digestive proteins into powerful anti-cancer therapeutics. The scientific results being shared at BioContact Quebec 2004 indicate that like many FDA approved chemotherapy treatments, EVade™ Ribonucleases are effective at killing cancer cells, but unlike chemotherapy treatments, EVade™ Ribonucleases are well tolerated in animals.
About Quintessence Biosciences
Quintessence Biosciences, Inc. is an early stage biopharmaceutical company focused on development of cancer therapies. The aim of the Company’s product development efforts is to develop effective cancer therapies that do not have harmful side effects.
For more information go to: http://www.quintbio.com
